**SDC 1 Symptoms and clinical findings in children and adults diagnosed with TBE during 2003-2008**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | **≤6 y** | **7-15 y** | **≤15 y** | **≥16 y** | ***p*-value** |
|  |  |  |  |  |  |
| *n* serological diagnoses | 8 | 30 | 38 | 249 |  |
|  |  |  |  |  |  |
| **anti-TBE serology**  |  |  |  |  |  |
| *n* inclusions in study | 5 (62.5%) | 27 (90.0%) | 32 (84.2%) | 191(76.7%) | n.s. |
| anti-TBE IgM+/G- | 0 | 1 (3.7%) | 1 (3.1%) | 10 (5.2%) | n.s. |
| anti-TBE IgM+/G+ | 5 (100%) | 26 (96.3%) | 31 (96.9%) | 178 (93.2%) | n.s. |
| anti-TBE IgM+ only in 2nd sample | 0 | 0 | 0 | 3 (1.6%) | n.s. |
|  |  |  |  |  |  |
| **medical history** |  |  |  |  |  |
| *n* patients evaluated | 5 (100%) | 27 (100%) | 32 (100%) | 191 (100%) | n.s. |
|  |  |  |  |  |  |
| back pain | 1 (20.0%) | 5 (18.5%) | 6 (18.8%) | 28 (14.7%) | n.s. |
| behavioral changes | 1 (20.0%) | 4 (14.8%) | 5 (15.6%) | 28 (14.7%) | n.s. |
| biphasic course | 2 (40.0%) | 16 (59.3%) | 18 (56.3%) | 89 (46.7%) | n.s. |
| headache | 3 (60.0%) | 23 (85.2%) | 26 (81.3%) | 142 (74.3%) | n.s. |
| malaise/fatigue | 4 (80.0%) | 17 (63.0%) | 21 (65.6%) | 83 (43.5%) | 0.035 |
| muscle pain | 2 (40.0%) | 6 (22.2%) | 8 (25.0%) | 71 (37.2%) | n.s. |
| seizures | 0 | 1 (3.7%) | 1 (3.1%) | 4 (2.1%) | n.s. |
| vertigo/balance problems | 2 (40.0%) | 11 (40.7%) | 13 (40.6%) | 82 (42.9%) | n.s. |
|  |  |  |  |  |  |
| history of tick-bite  | 2 (40.0%) | 18 (66.6%) | 20 (62.5%) | 142 (74.3%) | n.s. |
| visit to tick rich areas | 4 (80.0%) | 20 (74.1%) | 24 (75.0%) | 159 (83.2%) | n.s. |
|  |  |  |  |  |  |
| previous flavivirus infections | 0 | 1 (3.7%)b | 1 (3.1%)d | 1 (0.5%)f | n.s. |
| previous flavivirus vaccinations | 1 (20.0%)a | 4 (14.8%)c | 5 (15.6%)e | 47 (24.6%)g | n.s. |
|  |  |  |  |  |  |
| **clinical findings** |  |  |  |  |  |
| *n* patients evaluated | 5 (100%) | 25 (92.6%) | 30 (93.8%) | 181 (94.8%) | n.s. |
|  |  |  |  |  |  |
| sensory disturbances | 0 | 7 (28.0%) | 7 (23.3%) | 33 (18.2%) | n.s. |
| cognitive dysfunction | 1 (20.0%) | 2 (8.0%) | 3 (10.0%) | 39 (21.5%) | n.s. |
| cranial nerve palsy | 0  | 1 (4.0%) | 1 (3.3%) | 6 (3.3%) | n.s. |
| impaired general appearance | 2 (40.0%) | 4 (16.0%) | 6 (20.0%) | 76 (42.0%) | 0.028 |
| fever >38.5° | 3 (60.0%) | 19 (76.0%) | 22 (73.3%) | 88 (48.6%) | 0.022 |
| motor abnormalities | 1 (20.0%) | 3 (12.0%) | 4 (13.3%) | 52 (28.7%) | n.s. |
| neck stiffness | 1 (20.0%) | 8 (32.0%) | 8 (26.6%) | 37 (20.4%) | n.s. |
|  |  |  |  |  |  |
| **hospital stay** |  |  |  |  |  |
| *n* patients evaluated | 5 (100.0%) | 25 (92.6%) | 30 (93.8%) | 181 (94.8%) | n.s. |
| *n* patients admitted | 3 (60.0%) | 18 (72.0%) | 21 (70.0%) | 112 (61.9%) | n.s. |
| mean (range) of days admitted | 2.3 (1-7) | 4.3 (1-15) | 4.0 (1-15) | 6.1 (1-28) | 0.005 |
|  |  |  |  |  |  |
| **mortality** |  |  |  |  |  |
| *n* TBE related deaths | 0 | 0 | 0 | 3 (1.2%) | n.s. |
| *n* non-TBE related deaths | 0 | 0 | 0 | 5 (2.0%) | n.s. |

**y**, years; ***n***, numbers; **n.s.**, no statistical significance; **a**, TBE; **b**, Yellow fever; **c**, 1 Yellow fever + 3 TBE; **d**, Yellow fever; **e**, 1 Yellow fever + 4 TBE; **f**, TBE; **g**, 13 Yellow fever + 27 TBE + 7 Japanese encephalitis.